Condition: Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) · Sponsor: Regeneron Pharmaceuticals
Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat pediatric and adult participants who have severe-to profound and profound hearing loss due to changes in the otoferlin gene. The purpose of this study is to: * Learn about the safety of DB-OTO * Determine how well DB-OTO is tolerated (does not cause ongoing discomfort) * Evaluate the efficacy of DB-OTO (how well DB-OTO works)
This description comes directly from the study's public registry record.
Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
Always discuss trial participation with your own doctor first.
| University of California Los Angeles Medical Center | Los Angeles, California, United States | Recruiting |
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| Nemours Children s Clinic | Jacksonville, Florida, United States | Recruiting |
| Nemours Childrens Hospital | Orlando, Florida, United States | Recruiting |
| Boston Children's Hospital - Main | Boston, Massachusetts, United States | Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Seattle Children's Hospital | Seattle, Washington, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
| University Hospital Tubingen | Tübingen, Germany | Recruiting |
| Shinshu University Hospital | Matsumoto-shi, Nagano, Japan | Recruiting |
| Clinica Universidad de Navarra- Pamplona | Pamplona, Navarre, Spain | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05788536